摘要
幽门螺杆菌（Helicobacter pylori，H. pylori）感染是导致胃炎、消化性溃疡及胃癌等疾病的重要病因，其根除治疗一直是临床研究的重点。本研究旨在评估奥美拉唑联合阿莫西林和克拉霉素三联疗法在幽门螺杆菌感染患者中的疗效与安全性，并探讨其对胃黏膜炎症改善的作用。研究选取2019年至2021年间300例经胃镜检查和C-13呼气试验确诊的幽门螺杆菌感染者，随机分为实验组和对照组，实验组接受奥美拉唑、阿莫西林和克拉霉素三联治疗，对照组采用传统二联疗法。疗程结束后通过复查C-13呼气试验评估根除率，并记录不良反应发生情况。结果显示，实验组的幽门螺杆菌根除率为92.0%，显著高于对照组的74.7%（P0.05），且胃黏膜炎症改善程度更优。同时，实验组不良反应发生率较低，患者耐受性良好。研究表明，奥美拉唑联合阿莫西林和克拉霉素的三联疗法具有更高的根除率和更好的安全性，为幽门螺杆菌感染的临床治疗提供了优化方案，尤其在抗生素耐药性日益严重的背景下，该疗法展现了重要的应用价值。关键词：幽门螺杆菌；三联疗法；奥美拉唑；根除率；胃黏膜炎症
Efficacy Evaluation of Omeprazole in Combination with Amoxicillin and Clarithromycin for Helicobacter Pylori Infection Treatment
Abstract
Helicobacter pylori (H. pylori) infection is a critical etiological factor for gastritis, peptic ulcer disease, and gastric cancer, and its eradication has been a major focus of clinical research. This study aimed to evaluate the efficacy and safety of a triple therapy regimen consisting of omeprazole, amoxicillin, and clarithromycin in patients with H. pylori infection, as well as to investigate its effects on the improvement of gastric mucosal inflammation. A total of 300 patients diagnosed with H. pylori infection via gastroscopy and C-13 urea breath test between 2019 and 2021 were randomly assigned to an experimental group and a control group. The experimental group received triple therapy with omeprazole, amoxicillin, and clarithromycin, while the control group underwent conventional dual therapy. After the treatment course, eradication rates were assessed by repeat C-13 urea breath tests, and adverse reactions were recorded. The results showed that the eradication rate in the experimental group was 92.0%, significantly higher than 74.7% in the control group (P0.05), with superior improvement in gastric mucosal inflammation. Additionally, the incidence of adverse reactions was lower in the experimental group, indicating good patient tolerability. This study demonstrates that the triple therapy combining omeprazole, amoxicillin, and clarithromycin offers higher eradication rates and better safety profiles, providing an optimized treatment option for H. pylori infection. In particular, given the increasing prevalence of antibiotic resistance, this therapeutic approach exhibits significant application value in clinical practice.
Keywords: Helicobacter Pylori; Triple Therapy; Omeprazole; Eradication Rate; Gastric Mucosa Inflammation
目录
摘要 I
Abstract II
引言 1
1 幽门螺杆菌感染的治疗现状 1
1.1 幽门螺杆菌感染概述 1
1.2 当前治疗方案分析 2
1.3 联合疗法的研究意义 2
2 奥美拉唑的作用机制与疗效评估 3
2.1 奥美拉唑的药理特性 3
2.2 奥美拉唑在联合疗法中的作用 3
2.3 奥美拉唑疗效的影响因素 4
3 阿莫西林与克拉霉素的协同效应分析 4
3.1 阿莫西林的抗菌机制 4
3.2 克拉霉素的作用特点 4
3.3 两种药物的协同作用研究 5
4 联合疗法的临床应用与效果评价 5
4.1 临床试验设计与方法 5
4.2 疗效评价指标体系 6
4.3 不良反应及安全性分析 6
结论 7
参考文献 8
致谢 9
